Reframing Psoriasis Burden and Advancing Systemic Care in the Era of Novel Oral Agents

In this Dermatology Times Expert Perspectives episode, April Armstrong, MD, MPH, dermatologist, professor, and chief of dermatology at the University of California Los Angeles, discusses the evolving understanding of psoriasis as a systemic inflammatory disease and the implications for therapeutic decision-making. Moving beyond the historical view of psoriasis as a skin- or joint-limited condition, Armstrong emphasizes its broader impact, including associations with cardiovascular disease, mental health burden, and impaired social functioning. She highlights how effective disease control can translate not only to cutaneous clearance but also to meaningful improvements in overall patient well-being and quality of life.

Armstrong outlines contemporary criteria for identifying patients appropriate for systemic therapy, drawing on International Psoriasis Council recommendations. These include patients with ≥10% body surface area involvement, those with disease affecting high-impact sites such as the face, scalp, palms, soles, or genitals, and individuals with inadequate response to topical therapies. This framework suggests a shift toward earlier and more proactive systemic intervention.

The discussion also explores the rapidly evolving oral treatment landscape. Established agents such as apremilast and deucravacitinib have provided important alternatives to traditional systemic therapies with improved tolerability profiles. Building on this foundation, emerging next-generation oral therapies—including advanced TYK2 inhibitors and oral peptide-based approaches—are poised to narrow the historical efficacy gap between oral agents and biologics.

Armstrong further contextualizes these advances within psoriasis pathogenesis, highlighting the central role of TYK2 in mediating IL-23 signaling and downstream IL-17 activation. The observation that individuals with TYK2 deficiency do not develop psoriasis reinforces its validity as a therapeutic target. Collectively, these developments signal a transformative period in psoriasis management, where oral therapies may increasingly offer both high efficacy and favorable safety profiles.

Watch the next episode here.